Nonalcoholic Fatty Liver Disease Risk Higher in Individuals With Metabolically Healthy Obesity

Sarfaroj Khan 

July 13, 2020

Takeaway

  • Metabolically healthy individuals with overweight and obesity are at an increased risk of developing nonalcoholic fatty liver disease (NAFLD) compared with metabolically healthy normal weight individuals.

  • The risk is also higher in individuals who are normal weight with metabolic abnormalities.

Why this matters

  • Findings support that metabolically healthy obesity phenotype is a temporary state, and weight should be considered a risk factor for NAFLD even before other risk factors develop.

Study design

  • This retrospective study included 4,121,049 adults with no history of NAFLD or alcohol excess using data from The Health Improvement Network (THIN) database.

  • All participants were classified according to body mass index (BMI) category and metabolic abnormalities (diabetes, hypertension, and dyslipidaemia).

  • Primary outcome: diagnosis of NAFLD during follow-up.

  • Funding: None disclosed.

Key results

  • A total of 12,867 (0.3%) incident cases of NAFLD were recorded during a median follow-up period of 4.7 years (incidence rate, 0.55 per 1000 person-years).

  • Compared with individuals with normal weight and no metabolic abnormalities, the risk of developing NAFLD was significantly higher in:

    • individuals who were overweight (adjusted HR [aHR], 3.23; 95% CI, 2.98-3.49) and obese (aHR, 6.92; 95% CI, 6.40-7.48) with no metabolic abnormalities.

    • individuals who were normal weight with 1 (aHR, 2.27; 95% CI, 1.97-2.61) or ≥2 metabolic abnormalities (aHR, 2.39; 95% CI, 1.99-2.87).

Limitations

  • Retrospective design.

  • Possibility of misclassification bias.

 

Vusirikala A, Thomas T, Bhala N, Tahrani AA, Thomas GN, Nirantharakumar K. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord. 2020;20(1):96. doi: 10.1186/s12902-020-00582-9. PMID: 32605642.  Abstract.

This clinical summary first appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....